EGFR and glioblastoma: Unfortunately, even with the development of potent EGFR inhibitors, the oncogenic function of EGFR may still be retained in GBM cells through EGFR-PDGFRA receptor heterodimerization, suggesting the need for combinatorial treatment to effectively target EGFR activity [51].